A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma

References

• DeVita VT, Jr, Hubbard SM. Hodgkin’s disease. N Engl J Med 1993;328:560–655.
   PubMed Web of Science ®Google Scholar
• Yuen AR, Rosenberg SA, Hoppe RT, et al. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin’s disease. Blood 1997;89:814–822.
   PubMed Web of Science ®Google Scholar
• Lazarus HM, Rowlings PA, Zhang MJ, et al. Autotransplants for Hodgkin’s disease in patients never achieving remission: A report from the autologous blood and marrow transplant registry. J Clin Oncol 1999;17:534–545.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemo-therapy with autologous haemopoietic stem-cell transplan-tation for relapsed chemosensitive Hodgkin’s disease: A randomised trial. Lancet 2002;359:2065–2271.
   PubMed Web of Science ®Google Scholar
• Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: Results of a BNLI randomised trial. Lancet 1993;341:1051–1104.
   PubMed Web of Science ®Google Scholar
• Little R, Wittes RE, Longo DL, et al. Vinblastine for recurrent Hodgkin’s disease following autologous bone marrow trans-plant. J Chin Oncol 1998;16:584–658.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Bendandi M, Stefoni V, et al. Value of gemcitabine treatment in heavily pretreated Hodgkin’s disease patients. Haematologica 2000;85:926–999.
   PubMed Web of Science ®Google Scholar
• Santoro A, Bredenfeld H, Devizzi L, et al. Gemcitabine in the treatment of refractory Hodgkin’s disease: Results of a multicenter phase II study. J Chin Oncol 2000;18:2615–3269.
   PubMed Web of Science ®Google Scholar
• D’Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082–4405.
   PubMed Web of Science ®Google Scholar
• Baidas SM, Winer EP, Fleming GF, et al. Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Chin Oncol 2000;18:2710–3277.
   PubMed Web of Science ®Google Scholar
• Bertolini F, Mingrone W, Alietti A, et al. Thalidomide in multiple myeloma, myelodysplastic syndromes and histio-cytosis. Analysis of clinical results and of surrogate angiogen-esis markers. Ann Oncol 2001;12:987–990.
   PubMed Web of Science ®Google Scholar
• Drake MJ, Robson W, Mehta P, et al. An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer 2003;88:822–887.
   PubMed Web of Science ®Google Scholar
• Kaufmann H, Raderer M, Wohrer S, et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 2004;104: 2269–2271.
   PubMed Web of Science ®Google Scholar
• Piccaluga PP, Visani G, Pileri SA, et al. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study. Leukemia 2002;16: 1609–2114.
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565–2171.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI sponsored international working group. J Clin Oncol 1999;17:1244.
   PubMed Web of Science ®Google Scholar
• Ezdinli EZ, Stutzman L:. Vinblastine vs. nitrogen mustard therapy of Hodgkin’s disease. Cancer 1968;22:473–549.
   PubMed Web of Science ®Google Scholar
• Duggan DB, Petroni GR, Johnson JI,, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: Report of an intergroup trial. J Clin Oncol 2003;21:607–614.
   PubMed Web of Science ®Google Scholar
• Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002;99:4283–4497.
   PubMed Web of Science ®Google Scholar
• Doussis-Anagnostopoulou IA, Talks KL, Turley H, et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-reed-sternberg cells in Hodgkin’s disease. J Pathol 2002;197:677–883.
   PubMed Web of Science ®Google Scholar
• Giles FJ, Vose JM, Do KA, et al. Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin’s lymphoma or Hodgkin’s lymphoma. Leuk Res 2004;28: 595–604.
   PubMed Web of Science ®Google Scholar
• Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4–6.
   PubMed Web of Science ®Google Scholar
• Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 1996;31:213–221.
   PubMed Web of Science ®Google Scholar
• Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991;173:699–703.
   PubMed Web of Science ®Google Scholar
• Haslett PA, Corral LG, Albert M, et al. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998;187: 1885–2192.
   PubMed Web of Science ®Google Scholar
• McHugh SM, Rifkin IR, Deighton J, et al. The immuno-suppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Thl cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 1995;99: 160–217.
   PubMed Web of Science ®Google Scholar
• Pro B, Younes A, Albitar M, et al. Thalidomide for patients with recurrent lymphoma. Cancer 2004;100:1186–2119.
   PubMed Web of Science ®Google Scholar
• Younes A, Romaguera J, Hagemeister F, et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 2003;98:310–334.
   PubMed Web of Science ®Google Scholar
• Younes A, Pro B, Romaguera J, et al. Safety and efficacy of bortezomib (velcade) for the treatment of relapsed classical Hdogkin’s disease. Blood 2004;104:2638.
   Web of Science ®Google Scholar
• Leonard JP, Rosenblatt JD, Bartlett N, et al. Phase II study of SGN-30 (Anti-CD30 monoclonal antibody) in patients with refractory or recurrent Hodkgin’s disease. Blood 2004; 104:2635.
   PubMed Web of Science ®Google Scholar
• Corral LG, Kaplan G:. Immunomodulation by thalidomide and thalidomide analogues. Ann Rheum Dis 1999;58\(Suppl. 1): 1107–1113.
   Google Scholar
• Muller GW, Chen R, Huang SY, et al. Amino-substituted thalidomide analogs: Potent inhibitors of TNF-alpha pro-duction. Bioorg Med Chem Lett 1999;9:1625–2130.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000;96:2943–3250.
   PubMed Web of Science ®Google Scholar
• Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: Therapeutic applications. Leukemia 2001;15:1950–2161.
   PubMed Web of Science ®Google Scholar
• Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210–226.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Schlossman RI,, Weller E, et al. Immuno-modulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100:3063–3307.
   PubMed Web of Science ®Google Scholar
• Miller KC, Czuczman MS, Dimiceli L, et al. Antileukemic effects of novel immunomodulatory agent lenalidomide (L) with or without rituximab (R) in patients (pts) with relapsed (rel) or refractory (ref) chronic lymphocytic leukemia (CLL). Encouraging preliminary results of an ongoing phase II clinical study. J Clin Oncol 2005;23:6557.
   Web of Science ®Google Scholar